Fulcrum Asset Management LLP Purchases New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Fulcrum Asset Management LLP bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 6,307 shares of the biopharmaceutical company’s stock, valued at approximately $1,602,000.

Other large investors have also modified their holdings of the company. Legal & General Group Plc purchased a new position in Alnylam Pharmaceuticals during the second quarter worth about $278,321,000. Bank of New York Mellon Corp purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $148,128,000. Canada Pension Plan Investment Board purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $100,618,000. Korea Investment CORP purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $74,553,000. Finally, Pictet Asset Management Holding SA lifted its holdings in Alnylam Pharmaceuticals by 77.7% in the third quarter. Pictet Asset Management Holding SA now owns 495,168 shares of the biopharmaceutical company’s stock valued at $122,783,000 after acquiring an additional 216,555 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $151.64 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48. The stock has a market capitalization of $20.31 billion, a P/E ratio of 7.87 and a beta of 0.42. The company has a 50 day moving average price of $225.18 and a 200 day moving average price of $278.96. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $149.18 and a fifty-two week high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating the consensus estimate of $1.66 by $14.60. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.90 EPS. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current year.

Wall Street Analyst Weigh In

ALNY has been the subject of several analyst reports. Zacks Research lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Canaccord Genuity Group decreased their price target on Alnylam Pharmaceuticals from $429.00 to $323.00 and set a “buy” rating on the stock in a research note on Monday, November 2nd. JPMorgan Chase & Co. lowered their price target on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating for the company in a report on Wednesday, September 30th. TD Cowen cut their price objective on Alnylam Pharmaceuticals from $482.00 to $354.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $290.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $305.86.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.